These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
302 related articles for article (PubMed ID: 15307001)
1. The impact of meningococcal serogroup C conjugate vaccine in Scotland. Mooney JD; Christie P; Robertson C; Clarke SC Clin Infect Dis; 2004 Aug; 39(3):349-56. PubMed ID: 15307001 [TBL] [Abstract][Full Text] [Related]
2. The impact of childhood meningococcal serogroup C conjugate vaccine programs in Canada. Bettinger JA; Scheifele DW; Le Saux N; Halperin SA; Vaudry W; Tsang R; Pediatr Infect Dis J; 2009 Mar; 28(3):220-4. PubMed ID: 19209096 [TBL] [Abstract][Full Text] [Related]
3. Meningococcal C vaccines: the Canadian experience. De Wals P Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S280-4. PubMed ID: 15597070 [TBL] [Abstract][Full Text] [Related]
4. Rapid identification of herd effects with the introduction of serogroup C meningococcal conjugate vaccine in Ontario, Canada, 2000-2006. Kinlin LM; Jamieson F; Brown EM; Brown S; Rawte P; Dolman S; Drews SJ; Fisman DN Vaccine; 2009 Mar; 27(11):1735-40. PubMed ID: 19186206 [TBL] [Abstract][Full Text] [Related]
5. [Meningococcal disease in Spain, 1990-1997. Change in its epidemiological pattern]. de Mateo Ontañón S Rev Esp Salud Publica; 2000; 74(4):387-96. PubMed ID: 11031848 [TBL] [Abstract][Full Text] [Related]
6. Quadrivalent meningococcal ACYW-135 glycoconjugate vaccine for broader protection from infancy. Pace D Expert Rev Vaccines; 2009 May; 8(5):529-42. PubMed ID: 19397410 [TBL] [Abstract][Full Text] [Related]
7. Meningococcal disease: a review on available vaccines and vaccines in development. Bröker M; Fantoni S Minerva Med; 2007 Oct; 98(5):575-89. PubMed ID: 18043565 [TBL] [Abstract][Full Text] [Related]
8. Meningococcal B vaccine: new drug. The only vaccine against some serogroup B meningococci. Prescrire Int; 2008 Jun; 17(95):95-7. PubMed ID: 18623907 [TBL] [Abstract][Full Text] [Related]
9. Impact and effectiveness of meningococcal C conjugate vaccine following its introduction in Spain. Larrauri A; Cano R; García M; Mateo Sd Vaccine; 2005 Jul; 23(32):4097-100. PubMed ID: 15908059 [TBL] [Abstract][Full Text] [Related]
10. [Evolution of meningococcal disease in the community of Madrid. Effectiveness of antimeningococcal A+C vaccination]. Gutiérrez Rodríguez MA; Ramírez Fernández R; García Gutiérrez J; Moreno Civantos A; Hernando García M; Arce Arnáez A; Sendra Gutiérrez JM; Bueno Vallejos R Rev Esp Salud Publica; 2000; 74(4):397-403. PubMed ID: 11031849 [TBL] [Abstract][Full Text] [Related]
11. [The first effect of the national vaccination campaign against meningococcal-C disease: a rapid and sharp decrease in the number of patients]. de Greeff SC; de Melker HE; Spanjaard L; van den Hof S; Dankert J Ned Tijdschr Geneeskd; 2003 Jun; 147(23):1132-5. PubMed ID: 12822525 [TBL] [Abstract][Full Text] [Related]
12. Epidemiology of serogroup C and Y invasive meningococcal disease (IMD) in Ontario, 2000-2013: Vaccine program impact assessment. Wormsbecker AE; Wong K; Jamieson FB; Crowcroft NS; Deeks SL Vaccine; 2015 Oct; 33(42):5678-5683. PubMed ID: 26299749 [TBL] [Abstract][Full Text] [Related]
13. Recent epidemiological changes in meningococcal disease may be due to the displacement of serogroup A by serogroup C in Hefei City, China. Ni JD; Jin YH; Dai B; Wang XP; Liu DQ; Chen X; Zheng Y; Ye DQ Postgrad Med J; 2008 Feb; 84(988):87-92. PubMed ID: 18322129 [TBL] [Abstract][Full Text] [Related]
14. Meningococcal group C disease in Greece during 1993-2006: the impact of an unofficial single-dose vaccination scheme adopted by most paediatricians. Kafetzis DA; Stamboulidis KN; Tzanakaki G; Kourea Kremastinou J; Skevaki CL; Konstantopoulos A; Tsolia M Clin Microbiol Infect; 2007 May; 13(5):550-2. PubMed ID: 17378929 [TBL] [Abstract][Full Text] [Related]
15. Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Trotter CL; Andrews NJ; Kaczmarski EB; Miller E; Ramsay ME Lancet; 2004 Jul 24-30; 364(9431):365-7. PubMed ID: 15276396 [TBL] [Abstract][Full Text] [Related]
16. Effects of prior polysaccharide vaccination on magnitude, duration, and quality of immune responses to and safety profile of a meningococcal serogroup C tetanus toxoid conjugate vaccination in adults. Southern J; Deane S; Ashton L; Borrow R; Goldblatt D; Andrews N; Balmer P; Morris R; Kroll JS; Miller E Clin Diagn Lab Immunol; 2004 Nov; 11(6):1100-4. PubMed ID: 15539513 [TBL] [Abstract][Full Text] [Related]
17. Vaccinating adolescents against meningococcal disease in Canada: a cost-effectiveness analysis. De Wals P; Coudeville L; Trottier P; Chevat C; Erickson LJ; Nguyen VH Vaccine; 2007 Jul; 25(29):5433-40. PubMed ID: 17560695 [TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of conjugate meningococcal vaccination strategies in the United States. Shepard CW; Ortega-Sanchez IR; Scott RD; Rosenstein NE; Pediatrics; 2005 May; 115(5):1220-32. PubMed ID: 15867028 [TBL] [Abstract][Full Text] [Related]
19. Changes in the evolution of meningococcal disease, 2001-2008, Catalonia (Spain). Martínez AI; Dominguez A; Oviedo M; Minguell S; Jansa JM; Codina G; Vazquez JA; Vaccine; 2009 May; 27(25-26):3496-8. PubMed ID: 19200816 [TBL] [Abstract][Full Text] [Related]
20. Age-specific seroprevalence of serogroup C meningococcal serum bactericidal antibody activity and serogroup A, C, W135 and Y-specific IgG concentrations in the Turkish population during 2005. Ceyhan M; Yildirim I; Balmer P; Riley C; Laher G; Andrews N; Borrow R; Kurt N; Turgut M; Aydogan A; Ecevit C; Uysal G; Schultze V Vaccine; 2007 Oct; 25(41):7233-7. PubMed ID: 17707957 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]